Cargando…

Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs

BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Doo-Won, Ro, Woong-Bin, Sur, Jung-Hyang, Seung, Byung-Joon, Kang, Hyun-Min, Kim, Jong-Won, Park, See-Hyoung, Park, Hee-Myung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Veterinary Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636663/
https://www.ncbi.nlm.nih.gov/pubmed/34697923
http://dx.doi.org/10.4142/jvs.2021.22.e77
_version_ 1784608573446160384
author Song, Doo-Won
Ro, Woong-Bin
Sur, Jung-Hyang
Seung, Byung-Joon
Kang, Hyun-Min
Kim, Jong-Won
Park, See-Hyoung
Park, Hee-Myung
author_facet Song, Doo-Won
Ro, Woong-Bin
Sur, Jung-Hyang
Seung, Byung-Joon
Kang, Hyun-Min
Kim, Jong-Won
Park, See-Hyoung
Park, Hee-Myung
author_sort Song, Doo-Won
collection PubMed
description BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. OBJECTIVES: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. METHODS: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5–175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5–79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2–57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6–70.5]) in healthy dogs. CONCLUSIONS: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors.
format Online
Article
Text
id pubmed-8636663
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Veterinary Science
record_format MEDLINE/PubMed
spelling pubmed-86366632021-12-13 Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs Song, Doo-Won Ro, Woong-Bin Sur, Jung-Hyang Seung, Byung-Joon Kang, Hyun-Min Kim, Jong-Won Park, See-Hyoung Park, Hee-Myung J Vet Sci Original Article BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. OBJECTIVES: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. METHODS: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5–175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5–79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2–57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6–70.5]) in healthy dogs. CONCLUSIONS: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors. The Korean Society of Veterinary Science 2021-11 2021-09-08 /pmc/articles/PMC8636663/ /pubmed/34697923 http://dx.doi.org/10.4142/jvs.2021.22.e77 Text en © 2021 The Korean Society of Veterinary Science https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Song, Doo-Won
Ro, Woong-Bin
Sur, Jung-Hyang
Seung, Byung-Joon
Kang, Hyun-Min
Kim, Jong-Won
Park, See-Hyoung
Park, Hee-Myung
Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title_full Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title_fullStr Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title_full_unstemmed Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title_short Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
title_sort evaluation of circulating igf-i and igfbp-3 as biomarkers for tumors in dogs
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636663/
https://www.ncbi.nlm.nih.gov/pubmed/34697923
http://dx.doi.org/10.4142/jvs.2021.22.e77
work_keys_str_mv AT songdoowon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT rowoongbin evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT surjunghyang evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT seungbyungjoon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT kanghyunmin evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT kimjongwon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT parkseehyoung evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs
AT parkheemyung evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs